#United States #IDEAYA Biosciences #South San Francisco #targeted therapeutics #Nasdaq Listing Rule

IDEAYA Biosciences Introduces Inducement Grants for New Employees

On September 24, 2026, IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a prominent player in the field of precision medicine and oncology, made a significant announcement. The company revealed that its Compensation Committee had granted non-qualified stock options for a total of 94,000 shares to three newly onboarded employees. This move was executed in accordance with the Nasdaq Listing Rule 5635(c)(4), which governs the issuance of stock options as a material inducement for new hires.

The stock options were issued as part of the IDEAYA Biosciences 2023 Employment Inducement Incentive Award Plan, specifically designed to offer equity awards to individuals who are either newly hired or returning after a bona fide period of non-employment. This strategic incentive is vital for attracting top-tier talent in the competitive oncology sector.

The exercise price of the granted stock options stands at $36.74 per share, which reflects the closing price of IDEAYA’s stock on the Nasdaq Global Select Market on the date of grant. Notably, the options come with a 10-year term and will vest over four years. The vesting schedule outlines that 25% of the options will become available on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the subsequent three years. It's crucial to mention that the continued service of the employees will dictate the vesting of these options at each milestone.

About IDEAYA Biosciences

IDEAYA Biosciences is not only focused on the discovery and development of targeted therapeutics but is also dedicated to the commercialization of transformative therapies specifically for cancer treatments. Their innovative approach blends expertise in small-molecule drug discovery, structural biology, and bioinformatics with the robust internal capability to identify and validate translational biomarkers. This multifaceted strategy aims to produce tailored, potentially first-in-class targeted therapies that align with the genetic drivers of various cancers.

The company has established a comprehensive pipeline of product candidates, concentrating on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Their overarching mission is to advance the field of precision oncology by delivering therapies that are not only more selective and effective but also highly personalized. IDEAYA's goal is to significantly alter the course of diseases while improving clinical outcomes for cancer patients.

Conclusion

In conclusion, IDEAYA Biosciences' recent inducement grants clearly demonstrate its commitment to attracting skilled professionals in the oncology field, and their innovative approach to targeted medicine continues to position them at the forefront of the industry. As they move forward, the integration of new talent will likely enhance their ongoing projects in synthetic lethality and ADCs, bringing forth new hope for cancer treatment advancements.

For further inquiries regarding investor relations or media communications, IDEAYA encourages contact through their Chief Financial Officer, Joshua Bleharski, Ph.D., at [email protected].